The Group's principal activity is developing new human therapeutics based on its proprietary drug discovery and synthesis technologies. Its products include: Generic Fondaparinux, HA-irinotecan, The HyACT and Alchemia's Vast. The Group operates in Australia and the United States of America.
Alacra Alerts:
Receive alerts on the latest reports on Alchemia Limited
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
